Colorectal cancer biomarker and use thereof
AssigneesPublic University Corporation Nagoya City University, Aichi Prefecture
InventorsTakaya SHIMURA, Yusuke OKUDA, Hiromi KATAOKA, Ayumu TAGUCHI, Yuichi ABE
Life of this patent
Estimating the term…
Abstract
The present invention provides a colorectal cancer biomarker that enables simple and non-invasive determination of the presence or absence of the contraction of colorectal cancer with exceptional sensitivity and specificity. The colorectal cancer biomarker of the present invention is at least one urinary protein selected from the group consisting of DPEP1, TFF1, ANPEP, LGALS3, PRG4, CDH17, PIGR, TNFRSF10C, MEP1A, LGALS3BP, APOA1, LRG1, ENPEP, S100A11, MME, and ACP2.
Claims23
A method for testing for colorectal cancer, the method comprising:
- detecting at least one urinary protein selected from the group consisting of DPEP1, TFF1, ANPEP, LGALS3, PRG4, CDH17, PIGR, TNFRSF10C, MEP1A, LGALS3BP, APOA1, LRG1, ENPEP, S100A11, MME, and ACP2.
A method for diagnosing colorectal cancer, the method comprising:
- detecting at least one urinary protein selected from the group consisting of DPEP1, TFF1, ANPEP, LGALS3, PRG4, CDH17, PIGR, TNFRSF10C, MEP1A, LGALS3BP, APOA1, LRG1, ENPEP, S100A11, MME, and ACP2.
A colorectal cancer test kit used for a test of colorectal cancer, the kit comprising:
- a container for collecting urine of a subject;
- and
- a reagent for detecting at least one urinary protein selected from the group consisting of DPEP1, TFF1, ANPEP, LGALS3, PRG4, CDH17, PIGR, TNFRSF10C, MEP1A, LGALS3BP, APOA1, LRG1, ENPEP, S100A11, MME, and ACP2.
Use of a urinary protein for testing and/or diagnosis of colorectal cancer,
- wherein the urinary protein is at least one selected from the group consisting of DPEP1, TFF1, ANPEP, LGALS3, PRG4, CDH17, PIGR, TNFRSF10C, MEP1A, LGALS3BP, APOA1, LRG1, ENPEP, S100A11, MME, and ACP2.
Dependencies are inferred from the claim text.